Exploring biomarkers for prognosis in recurrent and metastatic colorectal cancer after surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study utilizes a multi-omics approach to identify biomarkers that may predict the prognosis of patients with recurrent and metastatic colorectal cancer following secondary radical resection. The research focuses on detecting DNA mutations and methylation patterns in tumor tissues using next-generation sequencing (NGS) technology, as well as analyzing circulating tumor DNA (ctDNA) in preoperative and postoperative blood samples. By correlating these molecular markers with patient outcomes, the study aims to enhance understanding of recurrence risk and improve prognostic accuracy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Colorectal cancer patients with first recurrence and metastasis after previous radical resection
2. Single site/organ metastasis is indicative of reoperation
3. Adenocarcinoma diagnosed by histology or cytology
4. At the time of signing the informed consent, the applicant must be 18 years old or older
5. Life expectancy is at least 12 weeks
6. ECOG score 0\~1

Exclusion Criteria:

1. Currently participating in the intervention study treatment, or receiving other drugs or study devices within 4 weeks before enrollment
2. Concurrent with other malignant tumors
3. The investigator determined that the patient had other serious diseases that might affect follow-up and short-term survival
4. Cardiac function NYHA class III or IV heart disease
5. The presence of definite peripheral nerve disease
6. There is definite hearing loss
7. Other researchers think it is not suitable for inclusion

Where it's running

• the Second Affiliated Hospital, Zhejiang University School of Medicine
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Lifeng Sun
• Email: sunlifeng@zju.edu.cn
• Phone: 13958103041

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Metastatic liver cancer patient registry from multiple Chinese centers

  This is a registry that collects real-world data on adults with liver metastases to understand patterns and prognosis and to support future research.

  Recruiting at 2 sites Anhui Provincial Hospital · Bengbu, Anhui and 2 other locations · NCT07602504

• Combination of balstilimab, botensilimab, and agenT-797 in pMMR colorectal cancer with liver metastases

  This trial tests whether a three-drug combination can help adults with metastatic, MSS colorectal cancer that has spread to the liver.

  Recruiting Phase 2 Scripps Health · La Jolla, California · NCT07550088

• Dual-target CAR-NK therapy for advanced colorectal cancer with CEA, GUCY2C, or HER2 markers

  This trial tests an off-the-shelf CAR-NK cell treatment that targets two tumor markers to see if it can shrink tumors in adults with advanced or metastatic colorectal cancer whose tumors express those markers.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07462650

• COLONYVAQ™: personalized quantum‑classical neoantigen peptide vaccine combined with chemotherapy and nivolumab for MSS stage III colorectal cancer

  This trial will test a personalized neoantigen peptide vaccine guided by quantum‑classical AI together with standard oxaliplatin‑based chemotherapy and nivolumab in patients with completely resected, microsatellite‑stable stage III colorectal cancer.

  Recruiting Early Phase 1 Biogenea Pharmaceuticals Ltd. · Thessaloniki · NCT07328087

• ABT-301 with tislelizumab and bevacizumab for pMMR/non‑MSI‑H advanced or metastatic colorectal cancer

  This trial will test whether adding the oral drug ABT-301 to fixed-dose tislelizumab and bevacizumab is safe and tolerable for adults with pMMR/non‑MSI‑H locally advanced or metastatic colorectal cancer who have had at least two prior systemic therapies.

  Recruiting Phase 1/2 Anbogen Therapeutics, Inc. · Liverpool, New South Wales and 14 other locations · NCT07244705

• Second-line regorafenib for advanced RAS-mutant colorectal cancer

  This trial will test whether regorafenib given as a less-intensive, personalized second-line option can preserve quality of life and extend survival for people with RAS‑mutant metastatic colorectal cancer who had a long first-line benefit or have only one metastatic site.

  Recruiting Phase 2 National Cancer Institute, Naples · Naples, Italy · NCT07213570

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.